Developer docs
API playgroundTry for free, no card

Search company profiles

Fera Pharmaceuticals

Full company profile

uuid0009o6z

Namestring
Fera Pharmaceuticals
Legal namestring
Fera Pharmaceuticals, LLC
Websiteurl
ferapharma.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Fera Pharmaceuticals is a privately held U.S. specialty pharmaceutical company headquartered in Locust Valley, New York, founded in 2009. Its stated mission is to preserve and expand treatment options for orphan and niche medical conditions, with a current commercial focus in ophthalmology. The company's flagship asset is Phospholine Iodide (echothiophate iodide for ophthalmic solution) 0.125%, acquired from Pfizer in August 2021 and officially launched in June 2022. Phospholine Iodide is positioned as the only commercially available acetylcholinesterase (AChE) inhibitor in eyecare, indicated for the reduction of elevated intraocular pressure (IOP) — including aphakic glaucoma in children and pseudophakic glaucoma in elderly patients — and for the diagnosis and treatment of accommodative esotropia. The product holds two FDA Orphan Drug Designations: for Stargardt Disease (April 2022) and for Naproxcinod for Sickle Cell Disease (March 2022).

Beyond Phospholine Iodide, the portfolio includes FDA-approved Avaclyr (acyclovir ophthalmic ointment, approved April 2019), Dexamethasone 4 mg tablets in unit-dose packaging (launched August 2020), and Erythromycin ophthalmic ointment distributed under an exclusive agreement with LSL Pharma Group (October 2023) to address a U.S. hospital drug shortage for newborn treatment. The pipeline reports four additional products: F-102 (early-stage orphan ophthalmic candidate), an ophthalmic antiviral (FDA-approved, launch pending), an ophthalmic corticosteroid (FDA-approved, launch pending), and an ophthalmic alpha-adrenergic blocking agent (FDA-approved, launch pending).

Fera operates a sales-led, distribution-partnered go-to-market motion. Phospholine Iodide reaches patients exclusively through Walgreens Specialty Pharmacy, which verifies insurance, administers the company's patient financial programs (commercial co-pay assistance capped at $100 per fill, a one-time 28-day QuickStart Program, and a Patient Assistance Program), coordinates overnight direct-to-patient delivery, and provides pharmacist consultation. Healthcare providers prescribe via fax referral form, e-prescribe, or direct phone call. The company also explicitly markets licensing, NDA/ANDA acquisition, and co-development opportunities to emerging pharma companies, framing itself as both a commercializer and a partner-of-choice for late-stage niche assets. Reporting lines are founder-led (Frank DellaFera, Founder & CEO) with Susan McDougal as EVP and Nicholas DellaFera handling licensing and partnership inquiries.

Short descriptiontext

Fera Pharmaceuticals is a privately held U.S. specialty pharmaceutical company focused on preserving treatment options for orphan and niche medical conditions, primarily in ophthalmology. It commercializes Phospholine Iodide, the only commercially available AChE inhibitor in eyecare, alongside Avaclyr, Dexamethasone, and a development pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLocust Valley, United States
HQ citystring
Locust Valley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
specialty pharmaceuticals, ophthalmic medications, orphan drug therapies, glaucoma treatments, prescription eye drops
Industry3 codes
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Ophthalmic Goods Manufacturing339115
  • Ophthalmic Goods Merchant Wholesalers423460
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Ophthalmic Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated from sales of specialty ophthalmic pharmaceutical products including Phospholine Iodide and other pipeline products. Products are distributed through specialty pharmacy partnerships with patient support programs.

ferapharma.com
2Distribution and Licensing
TypeLicensing Royalties
Description

Acquisition and licensing of pharmaceutical products and NDAs/ANDAs, with commercialization through distribution partnerships.

ferapharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Marketing or Sales, Operations, Personnel
Pricing details3 tiers
1Commercial Insurance Co-pay Assistance
ModelOtherBilling cadenceMonthly
Notes

Patients with commercial insurance may pay no more than $100 for their prescription

ferapharma.com
2QuickStart Program
ModelOtherBilling cadenceMulti-year contract
Notes

Provides a one-time, 28-day supply at no cost to eligible new patients who experience an insurance-related delay

ferapharma.com
3Patient Assistance Program (PAP)
ModelOtherBilling cadenceMulti-year contract
Notes

Provides eligible patients with their medication at no cost

ferapharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Fera Pharmaceuticals is a specialty pharmaceutical company that develops, acquires, and commercializes ophthalmic prescription drugs, with its core product Phospholine Iodide (echothiophate iodide 0.125%) — the only commercially available AChE inhibitor in eyecare — indicated for reducing elevated intraocular pressure and treating accommodative esotropia. The company also markets Avaclyr, Dexamethasone 4 mg Tablets, and distributes Erythromycin ophthalmic ointment, with a pipeline targeting additional ophthalmic indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • IOP decreased in 31 of 32 eyes in retrospective study of children with aphakic or pseudophakic glaucoma (mean baseline IOP decreased from 29.1 ± 5.3 mm Hg to 19.6 ± 6.7 mm Hg)
+1 more record
Product overview1 text field

Fera Pharmaceuticals is a specialty pharmaceutical company focused on ophthalmology, committed to preserving and expanding quality treatment options for orphan and niche medical conditions. The company operates with a single-product launch strategy anchored by Phospholine Iodide (echothiophate iodide for ophthalmic solution), the only commercially available AChE inhibitor in eyecare, indicated for elevated intraocular pressure and accommodative esotropia. The product portfolio includes FDA-approved Avaclyr (acyclovir ophthalmic ointment) and Dexamethasone 4 mg Tablets. The company also distributes Erythromycin ophthalmic ointment for newborns via an exclusive agreement with LSL Pharma Group. The pipeline includes four products: Antiviral (FDA approved, orphan drug, launch pending), Corticosteroid (FDA approved, launch pending), Alpha-adrenergic blocking agent (FDA approved, launch pending), and F-102 (orphan drug, early development). Phospholine Iodide is distributed through Walgreens Specialty Pharmacy with patient support programs including co-pay assistance, QuickStart, and Patient Assistance Programs.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-10-18
Description

Exclusive distribution agreement with LSL Pharma Group to alleviate drug shortage in U.S. hospitals. Given the scarcity of Erythromycin ophthalmic ointment in the U.S., the FDA granted Fera temporary discretion to import this vital medication for treatment of newborns. LSL's subsidiary Steri-Med Pharma initially supplies up to 25% of the four million doses required annually in the U.S. hospital market.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Walgreens Specialty Pharmacy serves as the primary specialty pharmacy partner for Phospholine Iodide distribution. The partnership includes insurance verification, administration of patient financial programs (co-pay assistance, QuickStart Program, Patient Assistance Program), coordinated overnight delivery direct to patients, and pharmacist consultation services. Healthcare providers can prescribe via fax referral form, e-prescribe, or phone.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

Fera Pharmaceuticals completed an agreement with Pfizer in August 2021 to acquire Phospholine Iodide. This acquisition brought the only commercially available AChE Inhibitor in eyecare under Fera's portfolio, aligning with their mission to preserve and expand quality treatment options for orphan and niche medical conditions.

4Emerging Pharmaceutical R&D Companies
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Fera offers commercialization and marketing support for emerging pharmaceutical research and development companies with promising late-stage product candidates, as well as product development partnerships with emphasis on reformulations, orphan drugs, and 505(b)2s.

ferapharma.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty ophthalmology pharmaceutical company focused on glaucoma and other eye diseases. Direct peer in the ophthalmic specialty pharma space with comparable size, focus on niche ophthalmic indications, and similar commercial model targeting ophthalmologists.

TypeDirect peer
Description

Specialty ophthalmic pharmaceutical company developing treatments for glaucoma, ocular surface disease, and rare eye conditions. Comparable in size and product strategy of targeting niche ophthalmology indications through specialty channels.

TypeDirect peer
Description

Specialty ophthalmic pharma focused on ocular surface diseases and rare eye conditions. Comparable in targeting niche ophthalmology indications with limited direct competition and specialty distribution models.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing therapies for ocular and inflammatory diseases. Comparable in orphan/specialty ophthalmic focus and small-cap specialty pharma profile with niche disease strategy.

TypeDirect peer
Description

European specialty ophthalmic pharmaceutical company focused on glaucoma and ocular surface diseases. Comparable in targeting niche ophthalmology indications with a small focused portfolio.

6Santen Pharmaceutical
TypeBroad incumbent
Description

Global specialty ophthalmic pharmaceutical company with broad portfolio in glaucoma, dry eye, and other eye conditions. Comparable in ophthalmic specialty pharma focus but operates at significantly larger scale with international presence.

TypeBroad incumbent
Description

Major ophthalmic company with broad portfolio spanning pharmaceuticals, surgical, and vision care. Operates Phospholine Iodide's prior market (glaucoma) at scale, making it the natural incumbent in Fera's addressable space.

TypeBroad incumbent
Description

Specialty pharmaceutical company with focus on rare diseases, immunology, and hospital products. Comparable in specialty/rare disease pharma strategy and in addressing drug shortages for niche indications.

TypeDirect peer
Description

Specialty pharmaceutical company with significant ophthalmic franchise including branded and generic ophthalmic products. Comparable in size, ophthalmic focus, and specialty distribution model.

TypeBroad incumbent
Description

European specialty pharmaceutical company with dedicated rare disease franchise. Comparable in mission to preserve and commercialize treatments for orphan and niche conditions, including ophthalmic rare diseases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fera Pharmaceuticals

Specialty Ophthalmic Pharmaceuticalsferapharma.com

Fera Pharmaceuticals is a privately held U.S. specialty pharmaceutical company focused on preserving treatment options for orphan and niche medical conditions, primarily in ophthalmology. It commercializes Phospholine Iodide, the only commercially available AChE inhibitor in eyecare, alongside Avaclyr, Dexamethasone, and a development pipeline.

What Fera Pharmaceuticals does

Fera Pharmaceuticals is a privately held U.S. specialty pharmaceutical company headquartered in Locust Valley, New York, founded in 2009. Its stated mission is to preserve and expand treatment options for orphan and niche medical conditions, with a current commercial focus in ophthalmology. The company's flagship asset is Phospholine Iodide (echothiophate iodide for ophthalmic solution) 0.125%, acquired from Pfizer in August 2021 and officially launched in June 2022. Phospholine Iodide is positioned as the only commercially available acetylcholinesterase (AChE) inhibitor in eyecare, indicated for the reduction of elevated intraocular pressure (IOP) — including aphakic glaucoma in children and pseudophakic glaucoma in elderly patients — and for the diagnosis and treatment of accommodative esotropia. The product holds two FDA Orphan Drug Designations: for Stargardt Disease (April 2022) and for Naproxcinod for Sickle Cell Disease (March 2022).

Beyond Phospholine Iodide, the portfolio includes FDA-approved Avaclyr (acyclovir ophthalmic ointment, approved April 2019), Dexamethasone 4 mg tablets in unit-dose packaging (launched August 2020), and Erythromycin ophthalmic ointment distributed under an exclusive agreement with LSL Pharma Group (October 2023) to address a U.S. hospital drug shortage for newborn treatment. The pipeline reports four additional products: F-102 (early-stage orphan ophthalmic candidate), an ophthalmic antiviral (FDA-approved, launch pending), an ophthalmic corticosteroid (FDA-approved, launch pending), and an ophthalmic alpha-adrenergic blocking agent (FDA-approved, launch pending).

Fera operates a sales-led, distribution-partnered go-to-market motion. Phospholine Iodide reaches patients exclusively through Walgreens Specialty Pharmacy, which verifies insurance, administers the company's patient financial programs (commercial co-pay assistance capped at $100 per fill, a one-time 28-day QuickStart Program, and a Patient Assistance Program), coordinates overnight direct-to-patient delivery, and provides pharmacist consultation. Healthcare providers prescribe via fax referral form, e-prescribe, or direct phone call. The company also explicitly markets licensing, NDA/ANDA acquisition, and co-development opportunities to emerging pharma companies, framing itself as both a commercializer and a partner-of-choice for late-stage niche assets. Reporting lines are founder-led (Frank DellaFera, Founder & CEO) with Susan McDougal as EVP and Nicholas DellaFera handling licensing and partnership inquiries.

Fera Pharmaceuticals firmographics

Firmographics
Name
Fera Pharmaceuticals
Legal name
Fera Pharmaceuticals, LLC
Website
https://ferapharma.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Fera Pharmaceuticals is a privately held U.S. specialty pharmaceutical company focused on preserving treatment options for orphan and niche medical conditions, primarily in ophthalmology. It commercializes Phospholine Iodide, the only commercially available AChE inhibitor in eyecare, alongside Avaclyr, Dexamethasone, and a development pipeline.
Ownership category
akta.pro rank

Fera Pharmaceuticals industry classification

Industry
Product category
Specialty Ophthalmic Pharmaceuticals
NAICS
Ophthalmic Goods Manufacturing (339115), Ophthalmic Goods Merchant Wholesalers (423460)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Ophthalmic medications
  • Orphan drug therapies
  • Glaucoma treatments
  • Prescription eye drops

Where Fera Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Locust Valley
HQ country
United States
HQ region
North America

Markets served

Fera Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Marketing or Sales, Operations, Personnel

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated from sales of specialty ophthalmic pharmaceutical products including Phospholine Iodide and other pipeline products. Products are distributed through specialty pharmacy partnerships with patient support programs.
  2. Distribution and Licensing: Acquisition and licensing of pharmaceutical products and NDAs/ANDAs, with commercialization through distribution partnerships.

Pricing tiers

ModelBillingPrice
OtherMonthlyCommercial Insurance Co-pay Assistance
OtherMulti-year contractQuickStart Program
OtherMulti-year contractPatient Assistance Program (PAP)

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Fera Pharmaceuticals product offering

Product offering

Core offering

Fera Pharmaceuticals is a specialty pharmaceutical company that develops, acquires, and commercializes ophthalmic prescription drugs, with its core product Phospholine Iodide (echothiophate iodide 0.125%) — the only commercially available AChE inhibitor in eyecare — indicated for reducing elevated intraocular pressure and treating accommodative esotropia. The company also markets Avaclyr, Dexamethasone 4 mg Tablets, and distributes Erythromycin ophthalmic ointment, with a pipeline targeting additional ophthalmic indications.

Product overview

Fera Pharmaceuticals is a specialty pharmaceutical company focused on ophthalmology, committed to preserving and expanding quality treatment options for orphan and niche medical conditions. The company operates with a single-product launch strategy anchored by Phospholine Iodide (echothiophate iodide for ophthalmic solution), the only commercially available AChE inhibitor in eyecare, indicated for elevated intraocular pressure and accommodative esotropia. The product portfolio includes FDA-approved Avaclyr (acyclovir ophthalmic ointment) and Dexamethasone 4 mg Tablets. The company also distributes Erythromycin ophthalmic ointment for newborns via an exclusive agreement with LSL Pharma Group. The pipeline includes four products: Antiviral (FDA approved, orphan drug, launch pending), Corticosteroid (FDA approved, launch pending), Alpha-adrenergic blocking agent (FDA approved, launch pending), and F-102 (orphan drug, early development). Phospholine Iodide is distributed through Walgreens Specialty Pharmacy with patient support programs including co-pay assistance, QuickStart, and Patient Assistance Programs.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • IOP decreased in 31 of 32 eyes in retrospective study of children with aphakic or pseudophakic glaucoma (mean baseline IOP decreased from 29.1 ± 5.3 mm Hg to 19.6 ± 6.7 mm Hg)
  • +1 more outcomes

Companies that use Fera Pharmaceuticals

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Fera Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Fera Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, major and minor.

  • LSL Pharma GroupcoreChannel Partner/ Reseller/ Distributor · 18 October 2023Exclusive distribution agreement with LSL Pharma Group to alleviate drug shortage in U.S. hospitals. Given the scarcity of Erythromycin ophthalmic ointment in the U.S., the FDA granted Fera temporary discretion to import this vital medication for treatment of newborns. LSL's subsidiary Steri-Med Pharma initially supplies up to 25% of the four million doses required annually in the U.S. hospital market.
  • Walgreens Specialty PharmacycoreChannel Partner/ Reseller/ DistributorWalgreens Specialty Pharmacy serves as the primary specialty pharmacy partner for Phospholine Iodide distribution. The partnership includes insurance verification, administration of patient financial programs (co-pay assistance, QuickStart Program, Patient Assistance Program), coordinated overnight delivery direct to patients, and pharmacist consultation services. Healthcare providers can prescribe via fax referral form, e-prescribe, or phone.
  • PfizermajorOEM/ Whitelabel/ Licensing PartnerFera Pharmaceuticals completed an agreement with Pfizer in August 2021 to acquire Phospholine Iodide. This acquisition brought the only commercially available AChE Inhibitor in eyecare under Fera's portfolio, aligning with their mission to preserve and expand quality treatment options for orphan and niche medical conditions.
  • Emerging Pharmaceutical R&D CompaniesminorStrategic or Co-development PartnerFera offers commercialization and marketing support for emerging pharmaceutical research and development companies with promising late-stage product candidates, as well as product development partnerships with emphasis on reformulations, orphan drugs, and 505(b)2s.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Fera Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Aerie Pharmaceuticals: Specialty ophthalmology pharmaceutical company focused on glaucoma and other eye diseases. Direct peer in the ophthalmic specialty pharma space with comparable size, focus on niche ophthalmic indications, and similar commercial model targeting ophthalmologists.
  • Ocular Therapeutix: Specialty ophthalmic pharmaceutical company developing treatments for glaucoma, ocular surface disease, and rare eye conditions. Comparable in size and product strategy of targeting niche ophthalmology indications through specialty channels.
  • Kala Pharmaceuticals: Specialty ophthalmic pharma focused on ocular surface diseases and rare eye conditions. Comparable in targeting niche ophthalmology indications with limited direct competition and specialty distribution models.
  • Aldeyra Therapeutics: Clinical-stage biopharmaceutical company developing therapies for ocular and inflammatory diseases. Comparable in orphan/specialty ophthalmic focus and small-cap specialty pharma profile with niche disease strategy.
  • Nicox Ophthalmic: European specialty ophthalmic pharmaceutical company focused on glaucoma and ocular surface diseases. Comparable in targeting niche ophthalmology indications with a small focused portfolio.
  • Akorn Pharmaceuticals: Specialty pharmaceutical company with significant ophthalmic franchise including branded and generic ophthalmic products. Comparable in size, ophthalmic focus, and specialty distribution model.

Broad incumbents

  • Santen Pharmaceutical: Global specialty ophthalmic pharmaceutical company with broad portfolio in glaucoma, dry eye, and other eye conditions. Comparable in ophthalmic specialty pharma focus but operates at significantly larger scale with international presence.
  • Bausch + Lomb: Major ophthalmic company with broad portfolio spanning pharmaceuticals, surgical, and vision care. Operates Phospholine Iodide's prior market (glaucoma) at scale, making it the natural incumbent in Fera's addressable space.
  • Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company with focus on rare diseases, immunology, and hospital products. Comparable in specialty/rare disease pharma strategy and in addressing drug shortages for niche indications.
  • Recordati Rare Diseases: European specialty pharmaceutical company with dedicated rare disease franchise. Comparable in mission to preserve and commercialize treatments for orphan and niche conditions, including ophthalmic rare diseases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Fera Pharmaceuticals social profiles

Digital presence

Fera Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fera Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles3 records

Fera Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fera Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fera Pharmaceuticals

What does Fera Pharmaceuticals do?

Fera Pharmaceuticals is a specialty pharmaceutical company that develops, acquires, and commercializes ophthalmic prescription drugs, with its core product Phospholine Iodide (echothiophate iodide 0.125%) — the only commercially available AChE inhibitor in eyecare — indicated for reducing elevated intraocular pressure and treating accommodative esotropia. The company also markets Avaclyr, Dexamethasone 4 mg Tablets, and distributes Erythromycin ophthalmic ointment, with a pipeline targeting additional ophthalmic indications.

Is Fera Pharmaceuticals a public or private company?

Fera Pharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Fera Pharmaceuticals founded?

Fera Pharmaceuticals was founded in 2009. It employs 11 to 50 people.

Where is Fera Pharmaceuticals based?

Fera Pharmaceuticals is headquartered in Locust Valley, United States, in the North America region.

How does Fera Pharmaceuticals make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are distribution and Licensing.

Who are Fera Pharmaceuticals's main competitors?

Direct peers on record are Aerie Pharmaceuticals, Ocular Therapeutix, Kala Pharmaceuticals, Aldeyra Therapeutics, Nicox Ophthalmic and Akorn Pharmaceuticals. Broad incumbents are Santen Pharmaceutical, Bausch + Lomb, Mallinckrodt Pharmaceuticals and Recordati Rare Diseases.

Does Fera Pharmaceuticals have an API?

No public API is recorded for Fera Pharmaceuticals.

What industry is Fera Pharmaceuticals in?

Fera Pharmaceuticals's product category is Specialty Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 339115 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireNicox’s Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell DiseaseThe U.S. FDA granted orphan drug designation for naproxcinod for sickle cell disease, affecting about 100,000 Americans. Nicox and Fera Pharmaceuticals announced the designation, with Fera responsible for U.S. development and a potential $40 million milestone if sales reach $1 billion.GlobeNewswireNicox Updates on Fera Pharmaceuticals’ Continuing Evaluation of NaproxcinodFera Pharmaceuticals decided to stop evaluating naproxcinod for COVID-19, focusing instead on sickle cell disease and other indications. Fera submitted a new Orphan Drug Designation application for sickle cell disease, addressing FDA concerns. Nicox retains rights outside the U.S. and may receive a $40 million milestone if naproxcinod reaches $1 billion in U.S. sales.GlobeNewswireNicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential Covid-19 Adjuvant TreatmentFera Pharmaceuticals will evaluate naproxcinod as a potential adjuvant treatment for COVID-19, with pre-clinical proof-of-concept studies planned in early 2021. The Nicox-Fera agreement is amended to include COVID-19, and Fera will receive warrants to acquire 10,000 Nicox shares. Fera will then meet with the FDA to plan clinical trials if results are positive.BenzingaNicox's Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential Covid-19 Adjuvant TreatmentFera Pharmaceuticals will evaluate naproxcinod as a potential adjuvant treatment for COVID-19, with pre-clinical studies planned in early 2021. Nicox and Fera amended their agreement to include COVID-19, granting Fera warrants for 10,000 Nicox shares. Fera will seek FDA approval for a New Drug Application if studies prove positive.GlobeNewswireNicox and Fera Pharmaceuticals to Focus on a Rare Disease Indication for NaproxcinodNicox and Fera Pharmaceuticals amended their 2015 naproxcinod license agreement to focus development on an undisclosed rare disease, potentially seeking an FDA orphan drug designation. The amendment raised a sales-based milestone to $40 million if annual U.S. sales reach $1 billion, with royalties unchanged at 7%.GlobeNewswireNicox and Fera Pharmaceuticals sign exclusive license agreement for naproxcinod in the U.S.Nicox and Fera Pharmaceuticals signed an exclusive license agreement for naproxcinod in the U.S., with Fera focusing on osteoarthritis. Nicox is eligible for up to $35 million in sales-based milestones plus 7% royalties on U.S. sales. Fera will finance all development and commercialization activities.